ArcherDX Blog



Oct
15
2018

Common tests for ROS1 translocations in lung cancer

A University of Colorado Cancer Center study published in the Journal of Thoracic Oncology highlights the limitations in common lab tests used to determine ROS1 status in lung cancer patients.


Oct
11
2018

Validation of the Archer FusionPlex Sarcoma kit

A paper published in The Journal for Molecular Diagnostics shows a direct comparison between the Archer FusionPlex Sarcoma panel and conventional methods for gene fusion detection, including fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR)


Oct
11
2018

Utility of Anchored Multiplex PCR for gene fusion detection®

Watch Dr. Cecilia Yeung's talk on using AMP™ technology for rapid identification of fusions in leukemias with Oxford Nanopore™ real-time sequencing from CGC 2018.


Oct
11
2018

Archer at AMP 2018

ArcherDX at the Association for Molecular Pathology annual meeting in San Antonio, TX from November 1-3, 2018


Oct
3
2018

Press release: Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration

ArcherDX and Merck KGaA, Darmstadt, Germany have entered into an agreement to develop and commercialize a next generation sequencing (NGS)-based companion diagnostic (CDx) assay.


Sep
4
2018

New features in Archer Analysis 6.0

Archer Analysis has been updated to version 6.0, making it more powerful and versatile than ever.


Aug
22
2018

Sensitive and quantitative TP53 variant calling by NGS

The Archer® VariantPlex® p53 Kit combines superior TP53 gene coverage with robust enrichment chemistry and an easy-to-use workflow to give you confident, sensitive and quantitative TP53 variant calling.


Aug
1
2018

High coverage and noise characterization of CEBPA for sensitive and specific variant detection

CEBPA mutations are important prognostic indicators in AML, however detecting CEBPA mutations by NGS is challenging due to high GC content. Here, we show that AMP-based NGS provides superior coverage of CEBPA and we demonstrate the use of normalization datasets to assess the noise at each base position to calculate the per-base variant detection sensitivity across CEBPA, expressed as 95 MDAF.


Apr
12
2018

Press release: Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).


Apr
4
2018

Cancer and ALK, RET, ROS1 gene fusions

Cancer is caused by mutations in specific genes. Many of these genes, including ALK, RET and ROS1, are called driver oncogenes because they are critical to the survival, growth and proliferation of cancer cells

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.